Patent ID: 6800280
Filing Date: 2004-10-05
Classification: A61K,Y10S

Abstract:
A method for treating an adult HIV-infected patient, comprising concurrent administration of one or more anti-retroviral agent(s), and 100-250 &mgr;g of human GM-CSF administered subcutaneously two times per week or three times per week for a time sufficient to induce an increase of at least 30% in the patient's CD4+ T-lymphocyte count, said time comprising at least eight weeks, wherein said anti-retroviral agent(s) comprises one protease inhibitor selected from the group consisting of indinavir, nelfinavir, ritonavir and saquinavir, and further wherein said patient has received the indinavir, nelfinavir, ritonavir or saquinavir for a minimum of eight weeks prior to receiving a first dose of GM-CSF.